TrialCNS oncology2018

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4

Daniela A Bota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.